MODERNA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116 USD | -0.96% |
|
-5.31% | +16.59% |
| 02/07 | Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling | MT |
| 02/07 | Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.59% | 44.44B | |
| +41.02% | 39.84B | |
| -10.62% | 37.68B | |
| +29.92% | 31.46B | |
| -9.23% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B | |
| -14.80% | 10.38B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine
